.Attributes Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a median follow-up of 11 months, patients with metastatic intestinal lumps that obtained biomarker-matched treatments based on circulating lump DNA profiling revealed a more significant scientific benefit than those receiving unparalleled therapy.